Which of the following medications are safe to use in patients with End-Stage Renal Disease (ESRD): Bromhexine, Chlorpheniramine (Chlorpheneramine), Pheniramine (Pheneramine), Guaifenesin (Guaiphenesin), Ambroxol, Terbutaline, Salbutamol (Albuterol), L-salbutamol (Levalbuterol), Menthol, Ammonium chloride, and Acebrophylline?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Medication Safety in ESRD: Drug-by-Drug Analysis

Among the listed medications, Salbutamol, L-salbutamol (Levalbuterol), Terbutaline, Menthol, Chlorpheniramine, and Pheniramine are safe in ESRD without dose adjustment, while Ammonium chloride must be avoided entirely, and Bromhexine, Guaifenesin, Ambroxol, and Acebrophylline require caution with limited safety data.

Beta-2 Agonists (Bronchodilators)

Safe Without Adjustment

  • Salbutamol (Albuterol), L-salbutamol (Levalbuterol), and Terbutaline are safe in ESRD because they undergo hepatic metabolism rather than renal elimination 1, 2.
  • These medications do not accumulate active metabolites that require renal clearance 3.
  • No dose adjustment is necessary even in patients receiving hemodialysis 4.

Antihistamines

Safe With Standard Dosing

  • Chlorpheniramine and Pheniramine can be used safely in ESRD as first-generation antihistamines with primarily hepatic metabolism 1.
  • However, monitor for enhanced sedation due to altered pharmacodynamics in uremia, which increases receptor sensitivity to sedating medications 5.
  • Avoid combining with other sedating medications or antihypertensives due to amplified fall risk and orthostatic hypotension 6, 7.

Expectorants and Mucolytics

Limited Data - Use With Caution

Guaifenesin:

  • Primarily hepatically metabolized, but specific ESRD safety data is lacking 1.
  • Generally considered low-risk due to minimal renal excretion, but formal pharmacokinetic studies in ESRD are absent 2.

Bromhexine and Ambroxol:

  • These mucolytics lack robust pharmacokinetic data in ESRD patients 4.
  • While hepatic metabolism predominates, potential metabolite accumulation in renal failure has not been adequately studied 3.
  • Use only if benefits clearly outweigh unknown risks, with close monitoring for adverse effects 5.

Acebrophylline:

  • This combination bronchodilator/mucolytic has insufficient safety data in ESRD 2.
  • Contains theophylline-like components that may have altered pharmacodynamics in renal insufficiency, with enhanced receptor sensitivity 5.
  • Avoid unless no alternatives exist, and monitor closely for toxicity 8.

Topical Agents

Safe for Use

  • Menthol is safe in ESRD as a topical agent with minimal systemic absorption 6.
  • Topical agents like menthol, lidocaine, and capsaicin are recommended as safe alternatives for symptom management in renal patients 6.

Absolutely Contraindicated

Ammonium Chloride - DO NOT USE

  • Ammonium chloride must be avoided entirely in ESRD due to severe risk of metabolic acidosis 8.
  • Patients with GFR <30 mL/min cannot adequately excrete the acid load, leading to life-threatening acidemia 8.
  • This represents a direct nephrotoxic and metabolic threat with potential for mortality 8.

Critical Clinical Pitfalls

Medication Reconciliation

  • Always verify current medication lists at every care transition, as medication discrepancies are a leading cause of morbidity in dialysis patients 8.
  • Bring medication bottles to all appointments and hospitalizations to ensure accurate reconciliation 8.

Metabolite Accumulation

  • Even hepatically metabolized drugs can accumulate toxic metabolites in ESRD if those metabolites require renal excretion 3.
  • Renal failure alters hepatic cytochrome P450 enzyme activity, potentially affecting drugs assumed to be "safe" due to liver metabolism 1, 2.

Enhanced Drug Sensitivity

  • Uremic toxins increase receptor sensitivity to many medications, particularly sedatives and cardiovascular drugs 5.
  • Standard doses may produce exaggerated effects even without drug accumulation 5.

Polypharmacy Interactions

  • ESRD patients typically take multiple medications that can interact through altered protein binding, competition for tubular secretion, or additive toxicities 8.
  • Withdraw potentially nephrotoxic or interacting agents when adding new medications 8.

References

Research

Renal disease and drug metabolism: an overview.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 1986

Research

Pharmacokinetics and dosage adjustment in patients with renal dysfunction.

European journal of clinical pharmacology, 2009

Research

Active drug metabolites and renal failure.

The American journal of medicine, 1977

Research

[Pharmacokinetic changes in renal failure].

Presse medicale (Paris, France : 1983), 2001

Guideline

Medication Management in End-Stage Renal Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Optimal Anxiety Management in Elderly Patients with Ischemic Cardiomyopathy and ICD

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What are the safety considerations for using Augmentin (amoxicillin-clavulanate) in patients with impaired renal function?
Is it safe to administer Bactrim (Trimethoprim/Sulfamethoxazole) 800/160, one tablet, after dialysis sessions in patients with impaired renal function?
What are the considerations for using Ambroxol (mucolytic agent) in patients with End-Stage Renal Disease (ESRD)?
What is the best management approach for an elderly female patient with hypotension, bradycardia, mildly elevated liver enzymes, and impaired renal function, considering her need for statin therapy and potential medication adjustments?
How should cyclobenzaprine be used in patients with impaired renal function?
What are the key considerations for the preoperative, intraoperative, and postoperative care of surgical neonates, particularly those with complex congenital conditions or premature infants?
What laboratory tests are recommended for a patient after adrenolectomy (adrenal gland removal), particularly those with a history of pheochromocytoma or Cushing's syndrome?
What are the potential adverse effects of dutasteride (5-alpha-reductase inhibitor) in older males with a history of benign prostatic hyperplasia (BPH) or androgenetic alopecia?
What is the dosing regimen for tirzepatide (dual GIP and GLP-1 receptor agonist) for weight loss in adults with a body mass index (BMI) of 30 or higher, or 27 or higher with at least one weight-related condition?
What are the typical steps and considerations for diagnosing and treating hyperhidrosis?
In a 22-year-old patient with rapidly growing lymph nodes, fatigue, pruritus, and lower back pain, is Diffuse Large B-Cell Lymphoma (DLBCL) or Hodgkin's lymphoma more likely?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.